CY1108645T1 - Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη - Google Patents
Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινηInfo
- Publication number
- CY1108645T1 CY1108645T1 CY20081101420T CY081101420T CY1108645T1 CY 1108645 T1 CY1108645 T1 CY 1108645T1 CY 20081101420 T CY20081101420 T CY 20081101420T CY 081101420 T CY081101420 T CY 081101420T CY 1108645 T1 CY1108645 T1 CY 1108645T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- lymphopoietin
- diagnosis
- temperatures
- temporary structural
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Θεραπεία για όγκους με χορηγώντας θυμική στρωματική λεμφοποιητίνη (TSLP). Διάγνωση νεοπλασμάτων τοποθετώντας σε επαφή ένα δείγμα με μια αντί-TSLP ή ένα υποδοχέα αντί-TSLP και ανίχνευση σχηματισμού ενός σύμπλοκου σντίσωμα:αντιγόνο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48826303P | 2003-07-18 | 2003-07-18 | |
EP04778434A EP1651247B1 (en) | 2003-07-18 | 2004-07-16 | Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108645T1 true CY1108645T1 (el) | 2014-04-09 |
Family
ID=34079411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101420T CY1108645T1 (el) | 2003-07-18 | 2008-12-09 | Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη |
Country Status (17)
Country | Link |
---|---|
US (3) | US20050048061A1 (el) |
EP (1) | EP1651247B1 (el) |
JP (3) | JP5436753B2 (el) |
AT (1) | ATE407691T1 (el) |
AU (1) | AU2004257781B2 (el) |
CA (1) | CA2532595A1 (el) |
CY (1) | CY1108645T1 (el) |
DE (1) | DE602004016522D1 (el) |
DK (1) | DK1651247T3 (el) |
ES (1) | ES2313076T3 (el) |
HR (1) | HRP20080617T3 (el) |
MX (1) | MXPA06000659A (el) |
NZ (1) | NZ544456A (el) |
PL (1) | PL1651247T3 (el) |
PT (1) | PT1651247E (el) |
SI (1) | SI1651247T1 (el) |
WO (1) | WO2005007186A1 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL143034A0 (en) | 1998-11-13 | 2002-04-21 | Immunex Corp | Human tslp dna and polypeptides |
US7288633B2 (en) | 2001-07-23 | 2007-10-30 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
PT1651247E (pt) * | 2003-07-18 | 2008-12-15 | Schering Corp | Tratamento e diagnóstico de neoplasmas utilizando linfopoietina de estroma tímico |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
SE532251C2 (sv) * | 2006-11-28 | 2009-11-24 | Theravac Pharmaceuticals Ab | Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering |
RU2457217C2 (ru) * | 2006-12-14 | 2012-07-27 | Шеринг-Плоу Лтд. | Собачий тимусный стромальный лимфопоэтический белок и его применение |
EA201000006A1 (ru) * | 2007-06-20 | 2010-10-29 | Айрм Ллк | Способы и композиции для лечения аллергических заболеваний |
US7982016B2 (en) * | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
EP2213682A1 (en) | 2009-01-30 | 2010-08-04 | Institut Curie | TSLP promotes immune evasion and persistence of viruses |
GB0918782D0 (en) * | 2009-10-26 | 2009-12-09 | St Georges Hosp Medical School | A protein as an adjuvant for a vaccine |
US20130096028A1 (en) * | 2010-06-28 | 2013-04-18 | Tohoku University | Cell capable of expressing tslp constantly and at high level, and method for screening for tslp modulator utilizing the cell |
WO2012015696A1 (en) * | 2010-07-26 | 2012-02-02 | Baylor Research Institute | Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer |
US20160052985A1 (en) | 2013-04-04 | 2016-02-25 | Ieo - Istituto Europeo Di Oncologia Srl | Thymic stromal lymphopoietin fragments and uses thereof |
WO2018156649A1 (en) * | 2017-02-22 | 2018-08-30 | Flagship Pioneering, Inc. | Compositions of t cell modulator (tcm) molecules and uses thereof |
EP3606548A4 (en) * | 2017-04-04 | 2021-03-24 | Loma Linda University | BIOLOGICAL PREPARATION FOR TREATMENT OF CANCER |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
US20030099947A1 (en) * | 1998-09-21 | 2003-05-29 | Bazan J. Fernando | Mammalian cytokines; related reagents and methods |
CA2343979C (en) | 1998-09-21 | 2011-11-15 | Schering Corporation | Human interleukin-b50, therapeutic uses |
IL143034A0 (en) * | 1998-11-13 | 2002-04-21 | Immunex Corp | Human tslp dna and polypeptides |
AU7026601A (en) * | 2000-06-28 | 2002-01-08 | Amgen Inc | Thymic stromal lymphopoietin receptor molecules and uses thereof |
US6890734B2 (en) | 2000-11-10 | 2005-05-10 | Schering Corporation | Nucleic acids encoding a cytokine receptor complex |
EP1341804A4 (en) * | 2000-11-17 | 2005-08-24 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
CN1234728C (zh) * | 2001-05-16 | 2006-01-04 | 上海睿星基因技术有限公司 | 新的人淋巴因子、其编码序列及用途 |
US7288633B2 (en) * | 2001-07-23 | 2007-10-30 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
NZ533987A (en) * | 2002-02-01 | 2007-04-27 | Schering Corp | Uses of mammalian cytokine; agonists and antagonists for modulating antigen presenting cell priming of T cells |
US20040022813A1 (en) * | 2002-08-05 | 2004-02-05 | Jean-Claude Bystryn | Shed antigen vaccine with dendritic cells adjuvant |
PT1651247E (pt) * | 2003-07-18 | 2008-12-15 | Schering Corp | Tratamento e diagnóstico de neoplasmas utilizando linfopoietina de estroma tímico |
-
2004
- 2004-07-16 PT PT04778434T patent/PT1651247E/pt unknown
- 2004-07-16 WO PCT/US2004/022928 patent/WO2005007186A1/en active Application Filing
- 2004-07-16 MX MXPA06000659A patent/MXPA06000659A/es active IP Right Grant
- 2004-07-16 AT AT04778434T patent/ATE407691T1/de active
- 2004-07-16 ES ES04778434T patent/ES2313076T3/es not_active Expired - Lifetime
- 2004-07-16 AU AU2004257781A patent/AU2004257781B2/en not_active Ceased
- 2004-07-16 SI SI200430939T patent/SI1651247T1/sl unknown
- 2004-07-16 CA CA002532595A patent/CA2532595A1/en not_active Abandoned
- 2004-07-16 PL PL04778434T patent/PL1651247T3/pl unknown
- 2004-07-16 EP EP04778434A patent/EP1651247B1/en not_active Expired - Lifetime
- 2004-07-16 NZ NZ544456A patent/NZ544456A/en not_active IP Right Cessation
- 2004-07-16 JP JP2006520375A patent/JP5436753B2/ja not_active Expired - Fee Related
- 2004-07-16 US US10/893,562 patent/US20050048061A1/en not_active Abandoned
- 2004-07-16 DK DK04778434T patent/DK1651247T3/da active
- 2004-07-16 DE DE602004016522T patent/DE602004016522D1/de not_active Expired - Lifetime
-
2007
- 2007-07-04 JP JP2007176805A patent/JP2007314547A/ja active Pending
-
2008
- 2008-11-26 HR HR20080617T patent/HRP20080617T3/xx unknown
- 2008-12-09 CY CY20081101420T patent/CY1108645T1/el unknown
-
2009
- 2009-08-27 US US12/548,784 patent/US8822405B2/en not_active Expired - Fee Related
-
2011
- 2011-08-19 JP JP2011179831A patent/JP2011236252A/ja active Pending
-
2014
- 2014-08-29 US US14/473,019 patent/US20140370025A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1651247B1 (en) | 2008-09-10 |
PT1651247E (pt) | 2008-12-15 |
US20050048061A1 (en) | 2005-03-03 |
DK1651247T3 (da) | 2009-01-12 |
JP2007314547A (ja) | 2007-12-06 |
CA2532595A1 (en) | 2005-01-27 |
US20100015132A1 (en) | 2010-01-21 |
DE602004016522D1 (de) | 2008-10-23 |
US8822405B2 (en) | 2014-09-02 |
AU2004257781A1 (en) | 2005-01-27 |
SI1651247T1 (sl) | 2009-02-28 |
AU2004257781B2 (en) | 2009-07-16 |
HRP20080617T3 (en) | 2009-01-31 |
EP1651247A1 (en) | 2006-05-03 |
JP5436753B2 (ja) | 2014-03-05 |
US20140370025A1 (en) | 2014-12-18 |
MXPA06000659A (es) | 2006-03-30 |
ATE407691T1 (de) | 2008-09-15 |
JP2011236252A (ja) | 2011-11-24 |
WO2005007186A1 (en) | 2005-01-27 |
PL1651247T3 (pl) | 2009-04-30 |
NZ544456A (en) | 2009-02-28 |
JP2007534623A (ja) | 2007-11-29 |
ES2313076T3 (es) | 2009-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108645T1 (el) | Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη | |
CY1109468T1 (el) | Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια | |
BRPI0510170B8 (pt) | composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto | |
NO20064193L (no) | fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser | |
DE602005014127D1 (de) | Medizinische vorrichtung und herstellungsverfahren dafür | |
BRPI0415361A (pt) | antagonistas do receptor muscarìnico de acetilcolina | |
DK1687049T3 (da) | Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer | |
EA201301072A1 (ru) | Антитела против il-23p19 и их применение | |
NO20064194L (no) | Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser | |
DK1708994T3 (da) | Aryloxyalkylcarbamatderivater, fremstilling og anvendelse herfra inden for terapi | |
BRPI0417823A (pt) | métodos para uso de bifidobactérias probióticas para animais de estimação | |
IS7960A (is) | Samsetningar og aðferðir til þess að meðhöndla krabbamein með því að nota IGSF9 og LIV-1 | |
ATE517340T1 (de) | Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren | |
ATE474462T1 (de) | Zusammensetzungen, kits und verfahren, bei denen eine zugesetzte borquelle eingesetzt wird | |
DE60336504D1 (de) | 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel | |
ITRM20030283A1 (it) | Mezzi terapeutici e diagnostici per i papillomi. | |
SE0202257D0 (sv) | Novel sequence information and methods for its use in diagnosis and therapy XVII | |
SE0201956D0 (sv) | Novel sequence information and methods for its use in diagnosis and therapy VI | |
SE0300293D0 (sv) | Novel sequence information and methods for its use in diagnosis and therapy XXV | |
SE0201867D0 (sv) | Novel sequence information and methods for its use in diagnosis and therapy I | |
SE0201955D0 (sv) | Novel sequence information and methods for its use in diagnosis and therapy V | |
SE0202260D0 (sv) | Novel sequence information and methods for its use in diagnosis and therapy XX | |
SE0300294D0 (sv) | Novel sequence information and methods for its use in diagnosis therapy XXVI | |
SE0202255D0 (sv) | Novel sequence information and methods for its use in diagnosis and therapy XV | |
SE0202251D0 (sv) | Novel sequence information and methods for its use in diagnosis and therapy XI |